Research prograame: small molecule therapeutics - Alveus Therapeutics/InterAx Biotech
Latest Information Update: 19 Feb 2026
At a glance
- Originator Alveus Therapeutics; InterAx Biotech
- Class Obesity therapies; Small molecules
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 15 Jan 2026 Alveus Therapeutics and InterAx Biotech collaborates for the development of small molecule therapeutics for Metabolic disorders
- 15 Jan 2026 Early research in Metabolic disorders in Switzerland (unspecified route)
- 15 Jan 2026 Early research in Metabolic disorders in Denmark (unspecified route)